Immunotherapy is currently one of the hottest areas in the pharma industry, and development of new targets continues apace. Already, several novel therapeutics have recently been commercialised and are making a positive difference to patients’ lives in therapeutic areas like oncology, autoimmunity and inflammation. Greg Bannish at Envigo discusses some of these therapies, including CAR-T therapies and checkpoint inhibitors, which came to fruition following decades of research.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/05/New-immunotherapies-need-new-models.pdf” width=”100%” height=”900px” style=”border:0;”]